Medpace Holdings (MEDP) stock jumps, and the company's rival contract research organizations also gain after its strong Q2 ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's ...

Medpace Holdings demonstrates strong Q2 2026 net new business awards, with a 1.13x net book-to-bill and $3.0B backlog. Learn ...

Medpace (MEDP) closed at $489.48 in the latest trading session, marking a +1.93% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

Medpace (MEDP) delivered earnings and revenue surprises of +4.17% and +1.12%, respectively, for the quarter ended June 2026.

Medpace stock surged by double digits Thursday, helped by a big bookings beat, rebounding from a poor start to the year.

Detailed price information for Charles River Laboratories (CRL-N) from The Globe and Mail including charting and trades.

Clinical trials can be wildly expensive for upstart drugmakers to run, which has led to a growth industry of outsourcing to scaled expert industry players like Medpace. In 2023 and 2024, ...

Detailed price information for Medpace Holdings Inc (MEDP-Q) from The Globe and Mail including charting and trades.

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com. CASE ALLEGATIONS: Medpace is a clinical contract research ...

Medpace Hldgs (NASDAQ:MEDP) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...